Navigation Links
Fragile X syndrome protein linked to breast cancer progression
Date:9/18/2013

Claudia Bagni (VIB/KU Leuven, Belgium, and the University of Rome Tor Vergata, Italy), has identified the way Fragile X Mental Retardation Protein or FMRP contributes to the progression of breast cancer. For this research the group of Bagni collaborated with colleagues from the VIB/KU Leuven departments of Bart De Strooper and Peter Carmeliet (VIB/KU Leuven), with Patrick Neven (UZ Leuven) and with several research centers and Hospitals in Italy and the UK. The researchers demonstrated that FMRP acts as a master switch controlling the levels of several proteins involved in different stages of aggressive breast cancer, including the invasion of cancer cells into blood vessels and the spread of these cancer cells to other tissues forming metastasis. The work is published on-line in EMBO Molecular Medicine.

Claudia Bagni: "Breast cancer is the most common form of cancer in women. It often comes back years after treatment and spreads throughout the body. We here show a correlation between the FMRP level in breast tissue and the chance of the spread of cancer to other organs. I hope that we can use this knowledge to develop a test to predict the likelihood of metastasis."

The authors identified high levels of FMRP in human breast cancer tissue microarrays and also examined the effects of FMRP levels in a mouse model to study breast cancer. In these mice, high levels of FMRP in primary breast cancer tumors were also linked to the spread of the cancer to the lungs and the development of metastasis. Importantly, reduction of FMRP, on the contrary lead to a decrease of metastasis formation and protection against breast cancer in individuals lacking this protein.

The role of FMRP is well known in the brain, where its absence leads to Fragile X Syn-drome, the most prevalent form of inherited intellectual disability in humans. The present study explored the direct relationship between the levels of FMRP and the progression of breast cancer.

"Previous studies indicated that patients with Fragile X Syndrome had a decreased risk of developing cancer but little is known about the molecular events that lead to this beneficial effect. We showed that high levels of the FMRP protein in human breast tissue samples are linked to increased risk of breast cancer and the spread of the disease to other tissues throughout the body," EMBO Member Claudia Bagni from VIB/KU Leuven, Belgium/ University of Rome Tor Vergata, Italy, who led the study, remarked. "Our results suggest that FMRP acts as a master regulator of a large group of mRNAs that are involved in multiple steps of cancer progression".

The researchers suggest that the levels of FMRP might be used as an indicator of aggressive breast cancer and could be used to predict the likelihood of the spread of cancer to other organs like the lung. In fact, the authors found that FMRP levels correlate with the highly aggressive Triple Negative Breast Cancer. Breast cancer is the most common form of cancer in women and has a poor prognosis. It often comes back years after treatment and spreads throughout the body.


'/>"/>

Contact: Sooike Stoops
info@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. MIND Institute researchers receive $1 million grant to study cognitive training in fragile X
2. Drug Shows Promise Against Fragile X Syndrome, Possibly Autism
3. Dr. Roger Reeves, 2012 Sisley-Jérôme Lejeune Prize Winner, Significantly Advances Understanding of the Biology of Down Syndrome Leading to New Avenues of Research
4. IBS Home Treatment
5. “IBS Miracle” Teaches People How to Get Rid of Their Irritable Bowel Syndrome (IBS) Symptoms Quickly – V kool
6. UCLA researchers describe new form of irritable bowel syndrome
7. Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome
8. Common blood pressure drug reduces aortic enlargement in Marfan syndrome
9. Transcranial direct current stimulation improves sleep in patients with post-polio syndrome
10. Dr. Donald Corenman, MD, Conducted a Two Year Study on the Effectiveness of Transforaminal Lumbar Interbody Fusion (TLIF) in Treating Discogenic Pain Syndrome (DPS)
11. No evidence of increased risk of Guillain-Barre syndrome following vaccination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s leading ... Big Game. Take the stress out of your party preparation – follow these easy, ... every stage of the game. , “The key to hosting a successful game-day party ...
(Date:2/5/2016)... ... 2016 , ... At its annual meeting held last week, the American Parkinson ... Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are ... , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016  Montoya Love is recognized by Continental Who,s ... Pharmaceuticals. Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range ... provides healthcare institutions, clinical laboratories and life science researchers ... the globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
(Date:2/4/2016)... 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... devices to treat life-threatening diseases, today announced results ... December 31, 2015. --> ... forth in our last quarterly call, we strategically ... long-term objective to establish the Aethlon Hemopurifier® as ...
Breaking Medicine Technology: